Maoto, a traditional herbal medicine, for post-exposure prophylaxis of Japanese healthcare workers exposed to COVID-19: a single-center study


This article was originally published here

J Infect Chemother. Mar 21, 2022: S1341-321X(22)00093-9. doi: 10.1016/j.jiac.2022.03.014. Online ahead of print.


BACKGROUND: Little research has been done on post-exposure prophylaxis (PEP) for COVID-19. This study was carried out to determine whether maoto, a traditional herbal medicine commonly used for diseases with symptoms similar to those of COVID-19, can be reused for post-exposure prophylaxis to prevent the spread of COVID-19. nosocomial infection with SARS-CoV-2.

METHODS: A cohort analysis was performed on data from 55 healthcare workers (HCWs) on whether to be infected with SARS-CoV-2 in a Japanese hospital experiencing a COVID-19 cluster in April 2021. Among these subjects, maoto granules for medical use were prescribed for PEP to 42 health workers and taken for three days in mid-April. Controls were 13 healthcare workers who rejected the use of maoto. The polymerase chain reaction was performed routinely once or twice a week or when a participant had symptoms of COVID-19.

RESULT: There were no substantive differences between the maoto and control groups by occupation, sex, or mean age. No serious adverse effects were observed. During the one-week observation period, significantly fewer subjects were diagnosed with COVID-19 in the maoto group (N=3, 7.1%) than in the control group (N=6, 46 .2%). The prophylactic efficacy of maoto was 84.5%.

CONCLUSION: Oral administration of maoto is suggested to be effective as a PEP against nosocomial COVID-19 infection.

PMID:35361537 | DO I:10.1016/j.jiac.2022.03.014


Comments are closed.